Celldex Halts Barzolvolimab Development for Atopic Dermatitis After Phase 2 Miss

Celldex’s Phase 2 trial of barzolvolimab in atopic dermatitis missed key efficacy goals. The company is ending development in eczema while advancing the drug in other indications.

Celldex Halts Barzolvolimab Development for Atopic Dermatitis After Phase 2 Miss
Credit: Celldex
Already have an account? Sign in.